证券代码：300622 证券简称：博士眼镜 公告编号：2024-072 博士眼镜连锁股份有限公司 第五届董事会第六次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 经审议，董事会认为公司《2024 年第三季度报告》的编制和审议程序符合相 关法律、行政法规、中国证监会和深圳证券交易所的相关规定，报告内容真实、 准确、完整地反映了公司 2024 年第三季度的实际经营情况，不存在任何虚假记 载、误导性陈述或者重大遗漏。 具体内容详见披露于巨潮资讯网（www.cninfo.com.cn）的相关公告。 三、备查文件 1、《博士眼镜连锁股份有限公司第五届董事会第六次会议决议》。 特此公告。 一、董事会会议召开情况 博士眼镜连锁股份有限公司（以下简称"公司"）第五届董事会第六次会议 通知于 2024 年 10 月 25 日以电子邮件的形式发出，会议于 2024 年 10 月 28 日 上午 10:30 在公司会议室以现场结合通讯表决等方式召开。本次会议应参与表决 董事 9 人，实际参与表决董事 9 人，会议由董事长 ALEXANDER LIU 先生召集和主 持 ...

Financial Performance - The company's revenue for Q3 2024 was ¥314,318,633.69, representing a 2.54% increase year-over-year[2] - Net profit attributable to shareholders for Q3 2024 was ¥31,099,762.48, a slight increase of 0.23% compared to the same period last year[2] - The net profit after deducting non-recurring gains and losses for Q3 2024 was ¥27,404,785.61, showing a decrease of 12.33% year-over-year[2] - Total operating revenue for Q3 2024 reached ¥915,266,819.34, a slight increase from ¥905,423,793.77 in Q3 2023, representing a growth of approximately 1.9%[18] - Operating profit for Q3 2024 was ¥103,858,040.01, down from ¥122,151,644.01 in the same period last year, indicating a decrease of about 15%[19] - Net profit for Q3 2024 was ¥82,799,233.94, compared to ¥99,688,950.56 in Q3 2023, reflecting a decline of approximately 16.9%[19] - Basic earnings per share for Q3 2024 were ¥0.48, down from ¥0.57 in Q3 2023, indicating a decrease of approximately 15.8%[20] - Other comprehensive income after tax for Q3 2024 was -¥228,217.17, compared to ¥3,239,930.72 in Q3 2023, indicating a significant decline[20] Assets and Liabilities - Total assets as of September 30, 2024, reached ¥1,284,443,916.97, reflecting a 14.50% increase from the end of the previous year[2] - The total liabilities increased to ¥483,890,002.54 in Q3 2024 from ¥309,486,440.76 in Q3 2023, marking an increase of about 56.3%[18] - Current assets totaled RMB 833,010,196.38, up from RMB 576,920,207.24, marking an increase of approximately 44.4%[17] - Non-current assets decreased to RMB 451,433,720.59 from RMB 544,854,867.37, a decline of about 17.1%[17] Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥225,458,103.93, down 9.90% compared to the same period last year[2] - Cash flow from operating activities for Q3 2024 was ¥933,226,854.92, up from ¥917,527,325.91 in Q3 2023, showing a growth of approximately 1.7%[21] - The company reported a net cash flow from operating activities of CNY 225.46 million, down from CNY 250.24 million, a decrease of 9.9%[22] - Net cash outflow from investing activities was CNY 226.23 million, worsening from a net outflow of CNY 157.04 million year-over-year[22] - Cash inflow from investment activities totaled CNY 590.12 million, significantly higher than CNY 103.02 million in the same period last year, indicating a growth of 471.5%[22] - Cash outflow for purchasing fixed assets and intangible assets was CNY 797.66 million, up from CNY 246.40 million, representing an increase of 223.5%[22] - Net cash flow from financing activities was negative at CNY 109.44 million, an improvement from a net outflow of CNY 130.12 million in the previous year[22] - The ending balance of cash and cash equivalents was CNY 81.38 million, a decrease from CNY 191.70 million year-over-year[22] Shareholder Information - The total number of common shareholders at the end of the reporting period is 21,922[10] - Louisa Fan holds 21.92% of shares, totaling 38,420,935 shares[10] - Alexander Liu holds 20.25% of shares, totaling 35,491,665 shares[10] - The total number of restricted shares at the beginning of the period was 58,718,368, with 2,325,954 shares released during the period[12] - The company has a total of 56,548,114 restricted shares remaining at the end of the period[12] - The company’s major shareholders, Louisa Fan and Alexander Liu, are identified as the actual controllers of the company[11] - The company has not reported any changes in the top 10 shareholders due to securities lending or borrowing[11] - The company has not disclosed any related party transactions among other shareholders[11] Dividends - The company approved a cash dividend of RMB 1.60 per 10 shares for the 2024 interim profit distribution, with the record date set for October 14, 2024[14] Inventory and Receivables - Inventory as of September 30, 2024, was ¥234,274,900, an increase of 34.32% from the end of the previous year, primarily due to preemptive stocking[6] - Accounts receivable rose to RMB 74,182,632.26 from RMB 64,348,941.76, indicating an increase of about 15%[16] - Other receivables increased to RMB 69,073,452.53 from RMB 51,611,965.06, showing a rise of about 33.8%[17] Legal Matters - The company is actively pursuing legal action to protect its trademark rights, which is expected to have no significant adverse impact on operations[15] - The company has initiated administrative litigation regarding the trademark disputes, with the court already reviewing the case[15] Accounting Standards - The company did not undergo an audit for the third quarter report[23] - The company will implement new accounting standards starting in 2024, affecting the financial statements[23]

证券代码：300622 证券简称：博士眼镜 编号：2024-12 博士眼镜连锁股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | --- | |-----------------------|-------|---------------------------------------------------|------------|----------------------------------------------------------| | | □ | 特定对象调研 | □ | 分析师会议 | | 投资者关系活动 | □ | 媒体采访 | □ | 业绩说明会 | | 类别 | □ | 新闻发布会 □ | | 路演活动 | | | ☑ | 现场参观 | | | | | □ | 其他 | | | | 参与单位名称 | | 金、时代伯乐（排名不分先后） | | 华创证券、信达澳亚、河床资本、东莞资管、中山资管、金信基 | | | | | | | | | | | | | | 时间 | 2024 | 年 10 月 24 日 | | | | 地点 | | 公司会议室 | ...

证券代码：300622 证券简称：博士眼镜 公告编号：2024-071 博士眼镜连锁股份有限公司 2024 年半年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 每股分红金额不变的原则对分红总额进行调整。 特别提示： 1、博士眼镜连锁股份有限公司（以下简称"公司"或"本公司"）2024 年 半年度权益分派方案为：公司以实施权益分派登记日登记的股份总数为基数，向 全体股东每 10 股派发现金股利人民币 1.60 元（含税），不送红股，不以资本公 积金转增股本。截至本公告披露日，公司总股本为 175,260,670 股，按照每股分 红金额不变的原则，预计派发现金红利 28,041,707.20 元（含税）。 2、本次权益分派实施后除权除息参考价=股权登记日收盘价-每股现金红利 =股权登记日收盘价-0.16 元/股。 1、公司于 2024 年 5 月 22 日召开 2023 年度股东大会审议通过了《关于提请 股东大会授权董事会决定 2024 年中期或春节前利润分配的议案》，授权董事会 全权办理 2024 年中期（包含半年度、前三季度）或春节前利润 ...

证券代码：300622 证券简称：博士眼镜 公告编号：2024-069 博士眼镜连锁股份有限公司 2024 年第二次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会没有否决或变更议案的情况发生； 2、本次股东大会不涉及变更前次股东大会决议。 一、会议召开和出席情况 （一）会议召开情况 7、本次股东大会的召集、召开符合《中华人民共和国公司法》《上市公司 股东大会规则》《深圳证券交易所创业板股票上市规则》等法律法规、规范性文 件及《博士眼镜连锁股份有限公司章程》的相关规定。 （二）会议出席情况 1、博士眼镜连锁股份有限公司（以下简称"公司"）于 2024 年 8 月 27 日 召开第五届董事会第五次会议审议通过了《关于召开 2024 年第二次临时股东大 会的议案》，通知内容详见 2024 年 8 月 29 日公司披露于巨潮资讯网 （www.cninfo.com.cn）的《博士眼镜连锁股份有限公司关于召开公司 2024 年第 二次临时股东大会的通知》（公告编号：2024-067）。 2、会议召开时间： （1）现场会议 ...

债权人如果提出要求公司清偿债务的，应根据《中华人民共和国公司法》等相 关法律法规的规定，向公司提出书面请求，并随附相关证明文件。 特此公告。 1 博士眼镜连锁股份有限公司 董事会 证券代码：300622 证券简称：博士眼镜 公告编号：2024-070 博士眼镜连锁股份有限公司 关于回购注销部分限制性股票的减资公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 博士眼镜连锁股份有限公司（以下简称"公司"）于 2024 年 7 月 5 日召开第五 届董事会第四次会议、2024 年 9 月 20 日召开 2024 年第二次临时股东大会，审议 通过了《关于调整 2021 年限制性股票与股票期权激励计划限制性股票回购价格及 回购注销部分限制性股票的议案》。鉴于限制性股票 2 名激励对象个人层面绩效考 核结果仅达到部分解除限售条件，公司回购注销上述 2 名激励对象已获授但尚未解 除限售的7,200 股限制性股票。回购注销完成后，公司注册资本相应减少7,200 元， 总股本相应减少 7,200 股。具体内容详见 2024 年 7 月 6 日公司披露于巨潮资讯网 （www. ...

北京│上海│深圳│杭州│广州│昆明│天津│成都│宁波│福州│西安│南京│南宁│济南│重庆│苏州│长沙│太原│武汉│贵阳│乌鲁木齐│郑州│石家庄│合肥│海南│青岛│拉孜 │香港│巴黎│马德里│斯德哥尔摩│纽约 BEIJING │SHANGHAI │SHENZHEN│HANGZHOU │GUANGZHOU│KUNMING │TIANJIN│CHENGDU│NINGBO │FUZHOU │XI'AN │NANJING│NANNING│JINAN│CHONGQING│SUZHOU│CHANGSHA│ 国浩律师（深圳）事务所 关于博士眼镜连锁股份有限公司 TAIYUAN│ WUHAN│GUIYANG│URUMQI│ZHENGZHOU│SHIJIAZHUANG│HEFEI│HAINAN│QINGDAO│LAZI│ HONG KONG│ PARIS│MADRID│STOCKHOLM│NEW YORK 博士眼镜 2024 年第二次临时股东大会法律意见书 实进行了核查和验证，现根据本所律师对事实的了解及对法律的理解，出具法律 意见如下： GLG/SZ/A2426/FY/2024-947 致：博士眼镜连锁股份有限公司 国浩律师（ ...

政旦志远（深圳）会计师事务所（特殊普通合伙）成立日期为 2005 年 1 月 12 日，注册地址为深圳市福田区莲花街道福新社区鹏程一路 9 号广电金融中心 14F，执行事务合伙人为张建栋。更名后，原"深圳大华国际会计师事务所（特 殊普通合伙）"的各项业务、权利和义务由"政旦志远（深圳）会计师事务所（特 殊普通合伙）"承继。 因此，公司 2024 年度财务审计机构名称变更为"政旦志远（深圳）会计师 事务所（特殊普通合伙）"。本次会计师事务所变更事项仅为名称变更，不涉及 主体资格变更，不属于更换或重新聘任会计师事务所事项。 特此公告。 证券代码：300622 证券简称：博士眼镜 公告编号：2024-068 博士眼镜连锁股份有限公司 关于会计师事务所更名的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 博士眼镜连锁股份有限公司（以下简称"公司"）于 2024 年 5 月 22 日召开 了 2023 年度股东大会，审议通过了《关于拟聘任会计师事务所的议案》，同意 聘任深圳大华国际会计师事务所（特殊普通合伙）为公司 2024 年度财务审计机 构。 公司于近日收到深 ...

Group 1: Business Strategy and Development - The company is leveraging its expertise in vision rehabilitation and prevention to explore new value in its professional capabilities [3] - As a full-channel eyewear retailer, the company is actively embracing the challenges of consumer connectivity, continuously expanding into shelf e-commerce, interest e-commerce, and local life services [3] - The company is committed to a talent-driven strategy, enhancing its professional workforce to support strategic goals [3] - The company aims to provide comprehensive vision correction solutions for smart glasses consumers, utilizing service experience to inform upstream product development [3] - The company will continue to seek merger and acquisition opportunities within the industry [3] Group 2: Online Channel Development - The company has established a presence on major social platforms like Weibo, Douyin, and Xiaohongshu, and has opened official stores on e-commerce platforms such as Tmall and JD [3] - In the first half of 2024, the company's total online transaction volume (GMV) reached 98.39 million yuan, a year-on-year increase of 0.93%, contributing 14.49% to overall revenue [3] - The official flagship stores on Tmall and JD saw a GMV increase of 27.11%, primarily driven by self-branded optical lenses [3] Group 3: Local Life Services - The company has opened official accounts on local life platforms like Douyin, Dazhong Dianping, and Ele.me, focusing on short video content to promote eye care knowledge and drive traffic to offline stores [4] - The company is enhancing its local life business through refined operations and optimized group purchase products [4] Group 4: Market Trends and Consumer Behavior - In the first half of 2024, functional lenses (excluding basic blue light blocking lenses) accounted for 32.04% of total lens sales, with a year-on-year growth of 45.29% [4] - There is a growing consumer focus on visual health, with increased willingness to invest in high-quality eyewear products and professional services [4]

Investment Rating - The report maintains a "Buy" rating for the company, with projected net profits of 140 million, 170 million, and 200 million yuan for 2024-2026, corresponding to P/E ratios of 34.3X, 28.5X, and 24.8X respectively [1] Core Views - The AR glasses market is experiencing rapid growth, with global and Chinese AR device shipments reaching 510,000 and 200,000 units in 2023, up 37.8% and 53.9% YoY respectively [1] - The company has a significant channel advantage, with a nationwide network of stores and partnerships with major AR players like Huawei, Rokid, and Thunderbird [1] - Customization capabilities in lenses are becoming a key competitive factor, with strong demand for digital, photochromic, and youth myopia control lenses [1] Industry Overview - The AR glasses market is highly concentrated, with the top 5 players accounting for 89.9% of the Chinese market in 2023 [1] - XREAL leads the global consumer AR market with an 81% share in H1 2022 [1] - The global AR device market is expected to reach 5 million units by 2027, with a CAGR of 77.0% from 2023-2027 [14] Company Strategy - The company is strengthening its position in the smart glasses sector through strategic investments and joint ventures, such as the planned collaboration with Thunderbird to develop a domestic version of Meta Ray-Ban [1] - It has established partnerships with multiple AR players, providing online prescription services and offline channel networks [1] - The company is expanding its retail network, with 515 stores nationwide as of 2023, including 495 directly operated stores [28] Financial Performance - Revenue is projected to grow from 1.176 billion yuan in 2023 to 1.771 billion yuan in 2026, with a CAGR of 14.6% [2] - Net profit attributable to shareholders is expected to increase from 128 million yuan in 2023 to 195 million yuan in 2026 [2] - The company's ROE is forecast to rise from 16.2% in 2023 to 18.5% in 2026 [2] Market Opportunities - The myopia control lens market in China is expected to exceed 30 million units by 2030, with a penetration rate of 30% and a market size of over 60 billion yuan [34] - The presbyopia lens market is driven by aging population and consumption upgrade trends, with annual demand of approximately 40 million pairs in China [36] - Emerging applications such as photochromic, night vision, and blue light blocking lenses present additional growth opportunities [42]